Clinical Examination Does Not Assist in the Detection of Systemic Relapse of Testicular Germ Cell Tumour

Cunniffe, N.G.; Robson, Jane; Mazhar, Danish; Williams, Michael

doi:10.1016/j.clon.2011.06.002

Cited by 9 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When considering whether to generalise these results to other cancers, we note that up to 70% of GCTs secrete sensitive and specific biomarkers (AFP, β‐hCG); hence, blood testing can detect disease. Physical examination adds little to follow‐up care in GCT (Cunniffe et al., 2012). As new circulating biomarkers are established, the implementation of similar initiatives will be increasingly feasible in other specialties, such as breast, colorectal or prostate cancer (Teagle & Gilbert, 2014).…”

Section: Discussionmentioning

confidence: 99%

“…Standard Follow‐up (SF) is an intensive programme of scheduled clinical investigations (blood markers, chest X‐rays and computed tomography [CT] scans) and consultations, stratified in frequency and length for risk of relapse and pursued in specialist regional cancer centres (Albers et al., 2015; Kollmannsberger et al., 2015). Consultations to promptly detect relapses do not require clinician‐led physical examinations in asymptomatic patients (Cunniffe, Robson, Mazhar, & Williams, 2012). However, specialist consultations are still needed for abnormal result, to identify/manage patients' concerns, symptoms, late effects, psychosocial problems and reduce adverse health behaviours which may increase cancer risks.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the “Shared Community Follow‐up” after a germ cell tumour—A novel initiative for remote cancer follow‐up enhanced by online patient‐reported outcome measures

et al. 2020

View full text Add to dashboard Cite

The aim of cancer follow-up is to detect relapses early, to monitor and manage early and late treatment toxicities, and to offer holistic post-treatment support (Heathcote et al., 2018). As more people live beyond cancer, the demand for follow-up monitoring increases (Maddams, Utley, & Møller, 2012; Stark et al., 2015). The problem is that cancer services will be unable to cater for the projected 4

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluation of the “Shared Community Follow‐up” after a germ cell tumour—A novel initiative for remote cancer follow‐up enhanced by online patient‐reported outcome measures

et al. 2020

View full text Add to dashboard Cite

show abstract

“…For cancers including breast, colorectal, and testicular, physical examination has not been shown to significantly contribute to the detection of recurrence. [8][9][10] A number of studies have shown that telephone follow-up can be as effective as face-to-face visits in addressing psychosocial effects of disease and treatment. 11,12 Nurses who conducted telephone follow-up for early stage breast cancer patients expressed confidence in their ability to deliver care through telemedicine platforms.…”

Section: Introductionmentioning

confidence: 99%

A Pilot Trial Using Telemedicine in Radiation Oncology: The Future of Health Care Is Virtual

Miller

Simone

Lombardo

et al. 2021

Telemedicine Reports

View full text Add to dashboard Cite

Background: Social determinants of health directly affect cancer survival. Driven by advances in technology and recent demands due to COVID-19, telemedicine has the ability to improve patient access to care, lower health care costs, and increase workflow efficiency. The role of telemedicine in radiation oncology is not established. Materials and Methods: We conducted an IRB-approved pilot trial using a telehealth platform for the first postradiation visit in patients with any cancer diagnosis. The primary endpoint was feasibility of using telehealth defined by completion of five telehealth visits per month in a single department. Secondary endpoints included the ability to assess patients appropriately, patient and physician satisfaction. Physicians were surveyed again during the pandemic to determine whether viewpoints changed. Results: Between May 27, 2016 and August 1, 2018, 37 patients were enrolled in the Telehealth in Post-operative Radiation Therapy (TelePORT) trial, with 24 evaluable patients who completed their scheduled telehealth visit. On average, 1.4 patients were accrued per month. All patients were satisfied with their care, had enough time with their physician and 85.7% believed the telehealth communication was excellent. All physicians were able to accurately assess the patient's symptoms via telehealth, whereas 82.3% felt they could accurately assess treatmentrelated toxicity. Physicians assessing skin toxicity from breast radiation were those who did not feel they were able to assess toxicity. Discussion and Conclusions: Both health care providers and patients have identified telemedicine as a suitable platform for radiation oncology visits. Although there are limitations, telemedicine has significant potential for increasing access of cancer care delivery in radiation oncology.

show abstract

“…Follow-up typically comprises regular physical examination, serum biomarker measurement [alpha-fetoprotein (AFP) and human choriogonadotropin (HCG)] (6), chest Xrays, and CT scans (7). However, doubt has been cast on the clinical value of physical examination (8,9), chest X-ray (10,11), and AFP/HCG markers, which are, for example, elevated in just 3% of seminoma patients at relapse (6). Thus for many patients, detection of relapse is dependent upon serial CT scans, which are associated with cumulative radiation burden and increased second cancer risk (12).…”

Section: Introductionmentioning

confidence: 99%

Cost Analysis of Noninvasive Blood-Based MicroRNA Testing Versus CT Scans for Follow-up in Patients With Testicular Germ-Cell Tumors

Charytonowicz

Aubrey

Bell

et al. 2019

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Conflicts of interest statement: The authors declare no potential conflicts of interest. For information, NC and MJM are developing and validating the technical and clinical performance of the non-invasive blood-based miRNA test described in this manuscript. RA is assisting NC and MJM in translating the test into clinical practice. HA, CB, DC, MF, and KT worked with RA to identify potential healthcare savings following future implementation of the miRNA test.

show abstract

Clinical Examination Does Not Assist in the Detection of Systemic Relapse of Testicular Germ Cell Tumour

Cited by 9 publications

References 25 publications

Evaluation of the “Shared Community Follow‐up” after a germ cell tumour—A novel initiative for remote cancer follow‐up enhanced by online patient‐reported outcome measures

Evaluation of the “Shared Community Follow‐up” after a germ cell tumour—A novel initiative for remote cancer follow‐up enhanced by online patient‐reported outcome measures

A Pilot Trial Using Telemedicine in Radiation Oncology: The Future of Health Care Is Virtual

Cost Analysis of Noninvasive Blood-Based MicroRNA Testing Versus CT Scans for Follow-up in Patients With Testicular Germ-Cell Tumors

Contact Info

Product

Resources

About